Mink Therapeutics, Inc. (INKT) Stock Price & Analysis
Mink Therapeutics, Inc. (INKT) rose 6.85% to USD 11.07 as of July 25, 2026 at 03:07 UTC, according to Nexqual real-time market data.
INKT last closed at USD 10.36; the session ranged USD 10.64–11.19 on volume of 20,448 shares. Market capitalization is $55.15M, with a 52-week range of USD 8.48–20.25 (NCM). Source: Nexqual, July 25, 2026 at 03:07 UTC.
Key Statistics (as of July 25, 2026 at 03:07 UTC)
| Price | USD 11.07 |
|---|---|
| Change | ▲ 6.85% (up) |
| Previous Close | USD 10.36 |
| Open | USD 10.64 |
| Day Range | USD 10.64 – 11.19 |
| 52-Week Range | USD 8.48 – 20.25 |
| Volume | 20,448 shares |
| Market Cap | $55.15M |
| Exchange | NCM |
Technical Analysis (INKT)
Nexqual's technical model rates INKT "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 03:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.83 (neutral) |
| vs SMA50 | Below (USD 11.41) |
| MACD | -0.26 (negative) |
Analyst Ratings (INKT)
Wall Street analysts rate INKT "None" based on 2 analysts, with a mean price target of USD 39 (range USD 35–43), per Nexqual as of July 25, 2026 at 03:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 39 |
| High Target | USD 43 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (INKT)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.6 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.57 vs est -0.77 ▲ beat |
| 2025-12-31 | USD -0.56 vs est -0.68 ▲ beat |
| 2025-09-30 | USD -0.65 vs est -0.86 ▲ beat |
| 2025-06-30 | USD -1.06 vs est -0.55 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Financials & Fundamentals (INKT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.38 |
| Total Cash | $9.53M |
| Total Debt | $0 |
| Free Cash Flow | $-5.11M |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Financial Health Score (INKT)
Nexqual rates Mink Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Mixed — No data |
Ownership (INKT)
| Insider Ownership | +60.67% |
|---|---|
| Institutional Ownership | +2.63% |
| Shares Outstanding | 4.98M |
| Float | 1.95M |
| Short % of Float | +4.62% |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Leadership (INKT)
Mink Therapeutics, Inc. is led by Jennifer S. Buell (age 50), Co-Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 03:07 UTC.
| Co-Founder, President, CEO & Director | Jennifer S. Buell (age 50) |
|---|---|
| Executive Chairman | Garo H. Armen (age 72) |
Major Backers & Investors (INKT)
Notable institutional backers of Mink Therapeutics, Inc. include Longbow Finance Sa, UBS Group AG, Fidelity, according to Nexqual as of July 25, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Longbow Finance Sa | 0.33% |
| UBS Group AG | 0.31% |
| Fidelity | 0.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.55% |
| Geode Capital | 0.35% |
| BlackRock | 0.12% |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
From Mink Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Even if we show improved efficacy or improved convenience of administration, third-party payors may deny or revoke the reimbursement status of our product candidates, if approved, or establish prices for our product candidates at levels that are too low to enable us to realize an appropriate return on our investment.
Partnerships
- Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATHM | Autohome Inc. | USD 21.11 | ▼ 1.86% |
| INSP | Inspire Medical Systems, Inc. | USD 49.19 | ▼ 2.4% |
| CNET | ZW Data Action Technologies Inc | USD 0.79 | ▼ 17.4% |
| CMRC | Commerce.com, Inc. - Series 1 | USD 2.71 | ▼ 0.37% |
| VRTS | Virtus Investment Partners, Inc | USD 165.66 | ▲ 0.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:07 UTC. This page is informational and not investment advice.